Abstract
Dexibuprofen is the single pharmacologically effective enantiomer of rac-ibuprofen. Racibuprofen and dexibuprofen differ in their physico-chemical properties, in terms of their pharmacological properties and their metabolic profiles. Several clinical trials and post-marketing surveillance studies were performed to broaden the findings on dexibuprofen. In the last 5 years 4836 patients have been exposed to dexibuprofen in clinical trials and PMS trials. Only in 3.7% of patients adverse drug reactions have been reported and 3 serious adverse drug reactions (0.06%) were observed. In the dose ratio of 1 : 0.5 (rac-ibuprofen vs. dexibuprofen) at least equivalent efficacy was proven in acute mild to severe somatic and visceral pain models. Dexibuprofen has proven at least comparable efficacy to diclofenac, naproxen and celecoxib and has shown a favourable tolerability. The results suggest that dexibuprofen processed in a special crystal form is a safe and effective treatment for different pain conditions.
Similar content being viewed by others
REFERENCES
Dionne, R. A. and McCullagh, L. (1998). Enhanced analgesia and supression of plasma ¯-endorphin by the S(+)-isomer of ibupropfen, Clin. Pharmacol. Ther. 63, 694–701.
Evans, A. M. (1992). Enantioselective pharmacodynamics and pharmacokinetics of chiral non-steriodal anti-inflammatory drugs, Eur. J. Clin. Pharmacol. 42, 237–256.
Evans, A. M. (1996). Pharmacodynamics and pharmacokinetics of the profens: enantioselectivity, clinical implications, and special reference to S(+)-ibuprofen, J. Clin. Pharmacol. 36, S7–S15.
Hawel, R., Klein, G., Singer, F., et al. (2003). Comparison of the efficacy and tolerability of dexibuprofen and celecoxib in the treatment of osteoarthritis of the hip, Int. J. Clin. Pharmacol. Ther. 41, 153–164.
Jamali, F. and Kunz-Dober, C. M. (1999). Pain-mediated altered absorption and metabolism of ibuprofen: an explanationfor decreased serumenantiomer concentrationafter dental surgery, Br. J. Clin. Pharmacol. 47, 391–396.
Janjikhel, R. K. and Bricker, J. D. (1999). Stereoselective dispositionof sustained release microphers of ibuprofen enantiomers in rats: II. Acute gastrointestinal toxicity, Drug Deliv. 6, 163–170.
Klein, G., Neff, H., Kullich, W., et al. (1992). S(+) versus racemic ibuprofen, Lancet 339, 681.
Langman, M. J. S., Weil, J. and Wainright, P. (1994). Risks of bleeding peptic ulcer associated with individual non-steriodal anti-inflammatory drugs, Lancet 343, 1075–1078.
Leising, G., Resel, R., Stelzer, F., et al. (1996). Physical aspects of dexibuprofen and racemic ibuprofen, J. Clin. Pharmacol. 36, 3S–6S.
Morihara, T., Chu, T., Ubeda, O., et al. (2002). Selective inhibition of Aβ42 production by NSAID R-enantiomers, J. Neurochem. 83, 1009–1012.
Rainsford, K. D. (Ed.) (1999). Pharmacology and toxicology of ibuprofen, in: Ibuprofen, a critical bibliographic review, pp. 145–275, Taylor & Francis, London.
Rudy, A. C., Bradley, J. D., Ryan, S. I., et al. (1992). Variability in the disposition of ibuprofen enantiomers in osteoarthritis patients, Ther. Drug Monitoring 14, 464–470.
Singer, F., Mayrhofer, F., Klein, G., et al. (2000). Evaluation of the efficacy and dose-response relationship of dexibuprofen(S(+)-ibuprofen) in patients with osteoarthritis of the hip and comparison with racemic ibuprofen using the WOMAC osteoarthritis index. Int. J. Clin. Pharmacol. Ther. 38, 15–24.
Tseng, C.-C. and Wolfe, M. M. (2000). Nonsteriodal anti-inflammatory drugs, Adv. Gastroenterol. 84, 1329–1344.
Vanderhoek, J. Y. and Bailey, M. J. (1984). Activation of a 15-lipoxygenase/ leukotriene pathway in human polymorphonuclear leucocytes by the anti-inflammatory agent ibuprofen, J. Biol. Chem. 259, 6752–6756.
Vanderhoek, J. Y., Ekborg, S. L. and Bailey, M. J. (1984). Effects of cell growth, differentiation, and transformation: clinical involvement of leucotrienes, J. Allergy Clin. Immunol. 74, 412–416.
Villanueva, M., Heckenberger, H., Palmer, S. M., et al. (1993). Equipotent inhibition by R-(–)-, S-(+)-and racemic ibuprofen of human polymorphonuclear cell function in vitro, Br. J. Clin. Pharmacol. 35, 235–242.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kaehler, S.T., Phleps, W. & Hesse, E. Dexibuprofen: pharmacology, therapeutic uses and safety. Inflammopharmacology 11, 371–383 (2003). https://doi.org/10.1163/156856003322699555
Issue Date:
DOI: https://doi.org/10.1163/156856003322699555